1.Transradial Versus Transfemoral Access for Bifurcation Percutaneous Coronary Intervention Using SecondGeneration Drug-Eluting Stent
Jung-Hee LEE ; Young Jin YOUN ; Ho Sung JEON ; Jun-Won LEE ; Sung Gyun AHN ; Junghan YOON ; Hyeon-Cheol GWON ; Young Bin SONG ; Ki Hong CHOI ; Hyo-Soo KIM ; Woo Jung CHUN ; Seung-Ho HUR ; Chang-Wook NAM ; Yun-Kyeong CHO ; Seung Hwan HAN ; Seung-Woon RHA ; In-Ho CHAE ; Jin-Ok JEONG ; Jung Ho HEO ; Do-Sun LIM ; Jong-Seon PARK ; Myeong-Ki HONG ; Joon-Hyung DOH ; Kwang Soo CHA ; Doo-Il KIM ; Sang Yeub LEE ; Kiyuk CHANG ; Byung-Hee HWANG ; So-Yeon CHOI ; Myung Ho JEONG ; Hyun-Jong LEE
Journal of Korean Medical Science 2024;39(10):e111-
Background:
The benefits of transradial access (TRA) over transfemoral access (TFA) for bifurcation percutaneous coronary intervention (PCI) are uncertain because of the limited availability of device selection. This study aimed to compare the procedural differences and the in-hospital and long-term outcomes of TRA and TFA for bifurcation PCI using secondgeneration drug-eluting stents (DESs).
Methods:
Based on data from the Coronary Bifurcation Stenting Registry III, a retrospective registry of 2,648 patients undergoing bifurcation PCI with second-generation DES from 21 centers in South Korea, patients were categorized into the TRA group (n = 1,507) or the TFA group (n = 1,141). After propensity score matching (PSM), procedural differences, in-hospital outcomes, and device-oriented composite outcomes (DOCOs; a composite of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization) were compared between the two groups (772 matched patients each group).
Results:
Despite well-balanced baseline clinical and lesion characteristics after PSM, the use of the two-stent strategy (14.2% vs. 23.7%, P = 0.001) and the incidence of in-hospital adverse outcomes, primarily driven by access site complications (2.2% vs. 4.4%, P = 0.015), were significantly lower in the TRA group than in the TFA group. At the 5-year follow-up, the incidence of DOCOs was similar between the groups (6.3% vs. 7.1%, P = 0.639).
Conclusion
The findings suggested that TRA may be safer than TFA for bifurcation PCI using second-generation DESs. Despite differences in treatment strategy, TRA was associated with similar long-term clinical outcomes as those of TFA. Therefore, TRA might be the preferred access for bifurcation PCI using second-generation DES.
2.Prognostic Value of Admission Blood Glucose Level in Critically Ill Patients Admitted to Cardiac Intensive Care Unit according to the Presence or Absence of Diabetes Mellitus
Sua KIM ; Soo Jin NA ; Taek Kyu PARK ; Joo Myung LEE ; Young Bin SONG ; Jin Oh CHOI ; Joo Yong HAHN ; Jin Ho CHOI ; Seung Hyuk CHOI ; Hyeon Cheol GWON ; Chi Ryang CHUNG ; Kyeongman JEON ; Gee Young SUH ; Jeong Hoon YANG
Journal of Korean Medical Science 2019;34(9):e70-
BACKGROUND: Admission blood glucose (BG) level is a predictor of mortality in critically ill patients with various conditions. However, limited data are available regarding this relationship in critically ill patients with cardiovascular diseases according to diabetic status. METHODS: A total of 1,780 patients (595 with diabetes) who were admitted to cardiac intensive care unit (CICU) were enrolled from a single center registry. Admission BG level was defined as maximal serum glucose level within 24 hours of admission. Patients were divided by admission BG level: group 1 (< 7.8 mmol/L), group 2 (7.8–10.9 mmol/L), group 3 (11.0–16.5 mmol/L), and group 4 (≥ 16.6 mmol/L). RESULTS: A total of 105 patients died in CICU (62 non-diabetic patients [5.2%] and 43 diabetic patients [7.9%]; P = 0.105). The CICU mortality rate increased with admission BG level (1.7%, 4.8%, 10.3%, and 18.8% from group 1 to group 4, respectively; P < 0.001). On multivariable analysis, hypertension, mechanical ventilator, continuous renal replacement therapy, acute physiology and chronic health evaluation II (APACHE II) score, and admission BG level significantly influenced CICU mortality in non-diabetic patients (group 1 vs. group 3: hazard ratio [HR], 3.31; 95% confidence interval [CI], 1.47–7.44; P = 0.004; group 1 vs. group 4: HR, 6.56; 95% CI, 2.76–15.58; P < 0.001). However, in diabetic patients, continuous renal replacement therapy and APACHE II score influenced CICU mortality but not admission BG level. CONCLUSION: Admission BG level was associated with increased CICU mortality in critically ill, non-diabetic patients admitted to CICU but not in diabetic patients.
APACHE
;
Blood Glucose
;
Cardiovascular Diseases
;
Critical Care
;
Critical Illness
;
Diabetes Mellitus
;
Humans
;
Hypertension
;
Intensive Care Units
;
Mortality
;
Prognosis
;
Renal Replacement Therapy
;
Ventilators, Mechanical
3.Erratum: The Practice Pattern of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.
Hyeon Cheol GWON ; Dong Woon JEON ; Hyun Jae KANG ; Jae Sik JANG ; Duk Woo PARK ; Dong Ho SHIN ; Keon Woong MOON ; Jung Sun KIM ; Juhan KIM ; Jang Whan BAE ; Seung Ho HUR ; Byung Ok KIM ; Donghoon CHOI ; Kyoo Rok HAN ; Hyo Soo KIM
Korean Circulation Journal 2017;47(4):541-541
In the article, “The Practice Pattern of Percutaneous Coronary Intervention in Korea.Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.” in Volume 47(3), page 320-327, indexed color of Class A and Class C has been changed.
4.Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice.
Kwi Hyun BAE ; Jung Beom SEO ; Yun A JUNG ; Hye Young SEO ; Sun Hee KANG ; Hui Jeon JEON ; Jae Man LEE ; Sungwoo LEE ; Jung Guk KIM ; In Kyu LEE ; Gwon Soo JUNG ; Keun Gyu PARK
Endocrinology and Metabolism 2017;32(1):115-123
BACKGROUND: Renal tubulointerstitial fibrosis is a common feature of the final stage of nearly all cause types of chronic kidney disease. Although classic peroxisome proliferator-activated receptor γ (PPARγ) agonists have a protective effect on diabetic nephropathy, much less is known about their direct effects in renal fibrosis. This study aimed to investigate possible beneficial effects of lobeglitazone, a novel PPARγ agonist, on renal fibrosis in mice. METHODS: We examined the effects of lobeglitazone on renal tubulointerstitial fibrosis in unilateral ureteral obstruction (UUO) induced renal fibrosis mice. We further defined the role of lobeglitazone on transforming growth factor (TGF)-signaling pathways in renal tubulointerstitial fibrosis through in vivo and in vitro study. RESULTS: Through hematoxylin/eosin and sirius red staining, we observed that lobeglitazone effectively attenuates UUO-induced renal atrophy and fibrosis. Immunohistochemical analysis in conjunction with quantitative reverse transcription polymerase chain reaction and Western blot analysis revealed that lobeglitazone treatment inhibited UUO-induced upregulation of renal Smad-3 phosphorylation, α-smooth muscle actin, plasminogen activator inhibitor 1, and type 1 collagen. In vitro experiments with rat mesangial cells and NRK-49F renal fibroblast cells suggested that the effects of lobeglitazone on UUO-induced renal fibrosis are mediated by inhibition of the TGF-β/Smad signaling pathway. CONCLUSION: The present study demonstrates that lobeglitazone has a protective effect on UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of non-diabetic origin renal disease.
Actins
;
Animals
;
Atrophy
;
Blotting, Western
;
Collagen Type I
;
Diabetic Nephropathies
;
Fibroblasts
;
Fibrosis*
;
In Vitro Techniques
;
Mesangial Cells
;
Mice*
;
Peroxisomes*
;
Phosphorylation
;
Plasminogen Activator Inhibitor 1
;
Polymerase Chain Reaction
;
Rats
;
Renal Insufficiency, Chronic
;
Reverse Transcription
;
Transforming Growth Factor beta
;
Transforming Growth Factors
;
Up-Regulation
;
Ureter*
;
Ureteral Obstruction*
5.The Current Status of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.
Jae Sik JANG ; Kyoo Rok HAN ; Keon Woong MOON ; Dong Woon JEON ; Dong Ho SHIN ; Jung Sun KIM ; Duk Woo PARK ; Hyun Jae KANG ; Juhan KIM ; Jang Whan BAE ; Seung Ho HUR ; Byung Ok KIM ; Donghoon CHOI ; Hyeon Cheol GWON ; Hyo Soo KIM
Korean Circulation Journal 2017;47(3):328-340
BACKGROUND AND OBJECTIVES: Although several multicenter registries have evaluated percutaneous coronary intervention (PCI) procedures in Korea, those databases have been limited by non-standardized data collection and lack of uniform reporting methods. We aimed to collect and report data from a standardized database to analyze PCI procedures throughout the country. MATERIALS AND METHODS: Both clinical and procedural data, as well as clinical outcomes data during hospital stay, were collected based on case report forms that used a standard set of 54 data elements. This report is based on 2014 Korean PCI registry cohort data. RESULTS: A total of 92 hospitals offered data on 44967 PCI procedures. The median age was 66.0 interquartile range 57.0-74.0 years, and 70.3% were men. Thirty-eight percent of patients presented with acute myocardial infarction and one-third of all PCI procedures were performed in an urgent or emergency setting. Non-invasive stress tests were performed in 13.9% of cases, while coronary computed tomography angiography was used in 13.7% of cases prior to PCI. Radial artery access was used in 56.1% of all PCI procedures. Devices that used PCI included drug-eluting stent, plain old balloon angioplasty, drug-eluting balloon, and bare-metal stent (around 91%, 19%, 6%, and 1% of all procedures, respectively). The incidences of in-hospital death, non-fatal myocardial infarction, and stroke were 2.3%, 1.6%, and 0.2%, respectively. CONCLUSION: These data may provide an overview of the current PCI practices and in-hospital outcomes in Korea and could be used as a foundation for developing treatment guidelines and nationwide clinical research.
Angiography
;
Angioplasty, Balloon
;
Cohort Studies*
;
Data Collection
;
Drug-Eluting Stents
;
Emergencies
;
Exercise Test
;
Humans
;
Incidence
;
Korea*
;
Length of Stay
;
Male
;
Myocardial Infarction
;
Percutaneous Coronary Intervention*
;
Radial Artery
;
Registries
;
Stents
;
Stroke
6.The Practice Pattern of Percutaneous Coronary Intervention in Korea: Based on Year 2014 Cohort of Korean Percutaneous Coronary Intervention (K-PCI) Registry.
Hyeon Cheol GWON ; Dong Woon JEON ; Hyun Jae KANG ; Jae Sik JANG ; Duk Woo PARK ; Dong Ho SHIN ; Keon Woong MOON ; Jung Sun KIM ; Juhan KIM ; Jang Whan BAE ; Seung Ho HUR ; Byung Ok KIM ; Donghoon CHOI ; Kyoo Rok HAN ; Hyo Soo KIM
Korean Circulation Journal 2017;47(3):320-327
BACKGROUND AND OBJECTIVES: Appropriate use criteria (AUC) was developed to improve the quality of percutaneous coronary intervention (PCI). However, these criteria should consider the current practice pattern in the country where they are being applied. MATERIALS AND METHODS: The algorithm for the Korean PCI practice pattern (KP3) was developed by modifying the United States-derived AUC in expert consensus meetings. KP3 class A was defined as any strategy with evidence from randomized trials that was more conservative for PCI than medical therapy or coronary artery bypass graft (CABG). Class C was defined as any strategy with less evidence from randomized trials and more aggressive for PCI than medical therapy or CABG. Class B was defined as a strategy that was partly class A and partly class C. We applied the KP3 classification system to the Korean PCI registry. RESULTS: The KP3 class A was noted in 67.7% of patients, class B in 28.8%, and class C in 3.5%. The median proportion of class C cases per center was 2.0%. The distribution of KP3 classes varied significantly depending on clinical and angiographic characteristics. The proportion of KP3 class C cases per center was not significantly dependent on PCI volume, but rather on the percentage of ACS cases in each center. CONCLUSION: We report the current PCI practice pattern by applying the new KP3 classification in a nationwide PCI registry. The results should be interpreted carefully with due regard for the complex relationships between the determining variables and the healthcare system in Korea.
Area Under Curve
;
Classification
;
Cohort Studies*
;
Consensus
;
Coronary Artery Bypass
;
Delivery of Health Care
;
Humans
;
Korea*
;
Percutaneous Coronary Intervention*
;
Transplants
7.Urinary arsenic species concentration in residents living near abandoned metal mines in South Korea.
Jin Yong CHUNG ; Byoung Gwon KIM ; Byung Kook LEE ; Jai Dong MOON ; Joon SAKONG ; Man Joong JEON ; Jung Duck PARK ; Byung Sun CHOI ; Nam Soo KIM ; Seung Do YU ; Jung Wook SEO ; Byeong Jin YE ; Hyoun Ju LIM ; Young Seoub HONG
Annals of Occupational and Environmental Medicine 2016;28(1):67-
BACKGROUND: Arsenic is a carcinogenic heavy metal that has a species-dependent health effects and abandoned metal mines are a source of significant arsenic exposure. Therefore, the aims of this study were to analyze urinary arsenic species and their concentration in residents living near abandoned metal mines and to monitor the environmental health effects of abandoned metal mines in Korea. METHODS: This study was performed in 2014 to assess urinary arsenic excretion patterns of residents living near abandoned metal mines in South Korea. Demographic data such as gender, age, mine working history, period of residency, dietary patterns, smoking and alcohol use, and type of potable water consumed were obtaining using a questionnaire. Informed consent was also obtained from all study subjects (n = 119). Urinary arsenic species were quantified using high performance liquid chromatography (HPLC) and inductively coupled plasma mass spectrometry (ICP/MS). RESULTS: The geometric mean of urinary arsenic (sum of dimethylarsinic acid, monomethylarsonic acid, As3+, and As5+) concentration was determined to be 131.98 μg/L (geometric mean; 95% CI, 116.72–149.23) while urinary inorganic arsenic (As3+ and As5+) concentration was 0.81 μg/L (95% CI, 0.53–1.23). 66.3% (n = 79) and 21.8% (n = 26) of these samples exceeded ATSDR reference values for urinary arsenic (>100 μg/L) and inorganic arsenic (>10 μg/L), respectively. Mean urinary arsenic concentrations (geometric mean, GM) were higher in women then in men, and increased with age. Of the five regions evaluated, while four regions had inorganic arsenic concentrations less than 0.40 μg/L, one region showed a significantly higher concentration (GM 15.48 μg/L; 95% CI, 7.51–31.91) which investigates further studies to identify etiological factors. CONCLUSION: We propose that the observed elevation in urinary arsenic concentration in residents living near abandoned metal mines may be due to environmental contamination from the abandoned metal mine. TRIAL REGISTRATION: Not Applicable (We do not have health care intervention on human participants).
Arsenic*
;
Cacodylic Acid
;
Chromatography, Liquid
;
Delivery of Health Care
;
Drinking Water
;
Environmental Health
;
Female
;
Humans
;
Informed Consent
;
Internship and Residency
;
Korea*
;
Male
;
Mass Spectrometry
;
Plasma
;
Reference Values
;
Smoke
;
Smoking
8.Renoprotective Effect of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, in Streptozotocin-Induced Type 1 Diabetic Mice.
Gwon Soo JUNG ; Jae Han JEON ; Mi Sun CHOE ; Sung Woo KIM ; In Kyu LEE ; Mi Kyung KIM ; Keun Gyu PARK
Diabetes & Metabolism Journal 2016;40(3):211-221
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used in the treatment of patients with type 2 diabetes and have proven protective effects on diabetic kidney disease (DKD). Whether DPP-4 inhibitors have renoprotective effects on insulin-deficient type 1 diabetes has not been comprehensively examined. The aim of this study was to determine whether gemigliptin, a new DPP-4 inhibitor, has renoprotective effects in streptozotocin (STZ)-induced type 1 diabetic mice. METHODS: Diabetes was induced by intraperitoneal administration of a single dose of STZ. Mice with diabetes were treated without or with gemigliptin (300 mg/kg) for 8 weeks. Morphological changes of the glomerular basement membrane (GBM) were observed by electron microscopy and periodic-acid Schiff staining. In addition, we measured blood glucose and urinary albumin excretion and evaluated fibrotic markers using immunohistochemical staining, quantitative reverse transcription polymerase chain reaction analysis, and Western blot analysis. RESULTS: Gemigliptin did not reduce the blood glucose levels of STZ-treated mice. In gemigliptin-treated mice with STZ, a significant reduction in urinary albumin excretion and GBM thickness was observed. Immunohistological examination revealed that gemigliptin attenuated renal fibrosis induced by STZ and decreased extracellular matrix protein levels, including those of type I collagen and fibronectin, and Smad3 phosphorylation. In cultured rat renal cells, gemigliptin inhibited transforming growth factor β-stimulated type I collagen and fibronectin mRNA and protein levels via down-regulation of Smad3 phosphorylation. CONCLUSION: Our data demonstrate that gemigliptin has renoprotective effects on DKD, regardless of its glucose-lowering effect, suggesting that it could be used to prevent DKD, including in patients with type 1 diabetes.
Animals
;
Blood Glucose
;
Blotting, Western
;
Collagen Type I
;
Diabetes Mellitus, Type 1
;
Diabetic Nephropathies
;
Down-Regulation
;
Extracellular Matrix
;
Fibronectins
;
Fibrosis
;
Glomerular Basement Membrane
;
Humans
;
Mice*
;
Microscopy, Electron
;
Phosphorylation
;
Polymerase Chain Reaction
;
Rats
;
Reverse Transcription
;
RNA, Messenger
;
Streptozocin
;
Transforming Growth Factors
9.Health-Related Quality-of-Life after Percutaneous Coronary Intervention in Patients with UA/NSTEMI and STEMI: the Korean Multicenter Registry.
Mi Jeong KIM ; Doo Soo JEON ; Hyeon Cheol GWON ; Soo Joong KIM ; Kiyuk CHANG ; Hyo Soo KIM ; Seung Jea TAHK
Journal of Korean Medical Science 2013;28(6):848-854
Compared with ST elevation myocardial infarction (STEMI), long-term outcomes are known to be worse in patients with unstable angina/non-STEMI (UA/NSTEMI), which might be related to the worse health status of patients with UA/STEMI. In patients with UA/NSTEMI and STEMI underwent percutaneous coronary intervention (PCI), angina-specific and general health-related quality-of-life (HRQOL) was investigated at baseline and at 30 days after PCI. Patients with UA/NSTEMI were older and had higher frequencies in female, diabetes and hypertension. After PCI, both angina-specific and general HRQOL scores were improved, but improvement was much more frequent in angina-related HRQOL of patients with UA/NSTEMI than those with STEMI (44.2% vs 36.8%, P < 0.001). Improvement was less common in general HRQOL. At 30-days after PCI, angina-specific HRQOL of the patients with UA/NSTEMI was comparable to those with STEMI (56.1 +/- 18.6 vs 56.6 +/- 18.7, P = 0.521), but general HRQOL was significantly lower (0.86 +/- 0.21 vs 0.89 +/- 0.17, P = 0.001) after adjusting baseline characteristics (P < 0.001). In conclusion, the general health status of those with UA/NSTEMI was not good even after optimal PCI. In addition to angina-specific therapy, comprehensive supportive care would be needed to improve the general health status of acute coronary syndrome survivors.
Aged
;
Angina, Unstable/physiopathology/*therapy
;
Asian Continental Ancestry Group
;
Female
;
Health Status
;
Humans
;
Male
;
Middle Aged
;
Myocardial Infarction/physiopathology/*therapy
;
Odds Ratio
;
*Percutaneous Coronary Intervention
;
*Quality of Life
;
Registries
;
Republic of Korea
10.Study of Compliance to Antihypertensive Medication in Korean Hypertensive Patients Using Medication Event Monitoring System.
Jidong SUNG ; Jin Ho CHOI ; Young Keun ON ; Sang Chol LEE ; Seung Woo PARK ; Hyeon Cheol GWON ; Eun Seok JEON ; June Soo KIM ; Duk Kyung KIM ; Sang Hun LEE ; Kyung Pyo HONG ; Jeong Euy PARK ; Jung Don SEO
Korean Circulation Journal 2005;35(11):821-826
BACKGROUND AND OBJECTIVES: Compliance to a prescribed antihypertensive regimen influences the management of hypertension in various steps, but studies on this issue are very rare in Korea. The medication event monitoring system (MEMS) is the gold standard in measurement of compliance, which is a special pill container, designed to electronically monitor drug intake patterns. Here, the authors investigated the compliance to the antihypertensive regimen in the cardiology practice of a tertiary care hospital using the MEMS. SUBJECTS AND METHODS: Monitoring using the MEMS was performed in 80 hypertensive patients during monotherapy. Demographic, clinical and psychological profiles were collected through a standardized questionnaire. The parameters used for compliance were the percentage of doses taken (PDT) and the percentage of doses taken correctly (PDTc), according to the prescribed regimen. RESULTS: The mean age of the patients and duration of monitoring were 53+/-10 years and 60+/-26 days, respectively. The median and range for the PDT and PDTc were 97% (88-100%) and 92% (80-97%), respectively. About 16% of patients showed relatively poor compliance (PDT<80%). Predicting factors for poor compliance were a recent history of self-discontinuation of drug treatment, not currently being on medication and a young age (p<0.05). Agreement between intuitive prediction by the physician and the actual compliance was closer to what would be expected by chance (kappa coefficient=-0.11). CONCLUSION: Although average compliance to the single drug antihypertensive regimen was relatively high in the cardiology practice of the tertiary care hospital in this study, a significant proportion of patients show low compliance. Special consideration should be given to patients with factors predictive of poor compliance. Investigation of compliances in other clinical settings is also warranted.
Cardiology
;
Compliance*
;
Drug Therapy
;
Humans
;
Hypertension
;
Korea
;
Micro-Electrical-Mechanical Systems
;
Patient Compliance
;
Tertiary Healthcare
;
Surveys and Questionnaires

Result Analysis
Print
Save
E-mail